Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRANDATE HCT vs ALDOCLOR-150
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TRANDATE HCT is a combination of labetalol, a non-selective beta-blocker with selective alpha-1 blocking activity, and hydrochlorothiazide, a thiazide diuretic. Labetalol reduces peripheral vascular resistance via alpha-1 blockade and decreases heart rate and cardiac output via beta-blockade. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, promoting diuresis and reducing plasma volume.
Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.
Treatment of hypertension,Management of hypertensive urgency (off-label)
Hypertension
Oral: 100 mg labetalol/25 mg hydrochlorothiazide twice daily, titrated based on blood pressure response; maximum 1200 mg labetalol/300 mg hydrochlorothiazide daily.
ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.
Labetalol: terminal elimination half-life is 6-8 hours (range 3-16 hours) consistent with twice-daily dosing. Hydrochlorothiazide: terminal half-life 9-10 hours (range 6-15 hours), prolonged in renal impairment.
Terminal elimination half-life is approximately 6-8 hours in patients with normal renal function. In patients with creatinine clearance <30 m L/min, half-life may be prolonged to 15-20 hours, necessitating dose adjustment.
Labetalol is extensively metabolized primarily via glucuronidation (direct conjugation) and minor CYP2D6-mediated oxidation to an inactive metabolite. Hydrochlorothiazide is not metabolized; it is excreted unchanged in urine.
Methyldopa is metabolized primarily via conjugation and decarboxylation; chlorothiazide is not extensively metabolized and is excreted unchanged in urine.
Labetalol is primarily excreted in urine as unchanged drug (approximately 55-60%) and as glucuronide conjugates. About 12-27% is excreted in feces via biliary elimination. Hydrochlorothiazide is excreted unchanged in urine (≥95%) via renal tubular secretion. Total renal elimination of labetalol: ~55-60% unchanged; HCTZ: ~95% unchanged.
Renal excretion of unchanged drug accounts for approximately 50-60% of the administered dose; hepatic metabolism contributes the remainder, with metabolites excreted via bile and feces. Less than 2% is excreted unchanged in feces.
Labetalol: ~50% bound to albumin. Hydrochlorothiazide: ~40-68% bound to albumin and alpha-1-acid glycoprotein.
Approximately 70-80% bound to plasma proteins, primarily albumin.
Labetalol: Vd 3-16 L/kg (mean 11 L/kg), indicating extensive tissue distribution. Hydrochlorothiazide: Vd 0.8-1.5 L/kg (mean 1 L/kg), limited distribution.
Vd is approximately 0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid and limited tissue binding.
Labetalol: oral bioavailability is 25-40% due to extensive first-pass metabolism. Hydrochlorothiazide: oral bioavailability is 65-75% (fasted).
Oral bioavailability is approximately 70-80%; food does not significantly alter absorption.
GFR 30-90 m L/min: No adjustment. GFR <30 m L/min: Contraindicated due to hydrochlorothiazide component.
Contraindicated in patients with GFR <30 m L/min. For GFR 30-50 m L/min, reduce frequency to every other day. For GFR >50 m L/min, no adjustment necessary.
Child-Pugh A: Use with caution; reduce labetalol dose. Child-Pugh B or C: Contraindicated due to extensive hepatic metabolism of labetalol.
Child-Pugh Class A: No adjustment necessary. Child-Pugh Class B: Reduce dose by 50% or extend dosing interval. Child-Pugh Class C: Use is not recommended due to risk of hepatic encephalopathy and fluid retention.
Not recommended; safety and efficacy not established for labetalol/hydrochlorothiazide combination.
Not recommended for pediatric use due to lack of safety and efficacy data in patients under 18 years of age.
Start at lowest dose (100/25 mg daily); titrate slowly due to increased risk of hypotension and electrolyte imbalance.
Initiate at lower dose (e.g., half tablet) due to increased sensitivity to antihypertensive effects, risk of orthostatic hypotension, and impaired renal function. Monitor blood pressure and electrolytes closely.
None
None.
Beta-blocker withdrawal: abrupt discontinuation may exacerbate angina or precipitate myocardial infarction in patients with coronary artery disease. Bronchospasm: avoid in patients with bronchial asthma or COPD. Heart failure: caution in patients with decompensated heart failure; may precipitate worsening. Peripheral vascular disease: may worsen symptoms. Hepatic impairment: labetalol is hepatically metabolized; use caution. Renal impairment: hydrochlorothiazide may be ineffective with Cr Cl <30 m L/min. Electrolyte disturbances: monitor potassium, sodium, magnesium; risk of hypokalemia, hyponatremia, hypomagnesemia. Hyperuricemia: can precipitate gout. Photosensitivity: with hydrochlorothiazide. Exacerbation of systemic lupus erythematosus: reported with thiazides. DM: beta-blockers may mask hypoglycemia. Surgery: withdrawal before elective surgery recommended.
May cause sedation, dizziness, and orthostatic hypotension. Avoid abrupt discontinuation. Use with caution in patients with impaired renal function, liver disease, or history of depression. Monitor for electrolyte imbalance, especially hypokalemia, due to chlorothiazide component.,Methyldopa may cause positive direct Coombs test, hemolytic anemia, and liver disorders. Discontinue if jaundice or liver abnormalities occur.
Absolute: sinus bradycardia, heart block greater than first degree, cardiogenic shock, decompensated heart failure, bronchial asthma, hypersensitivity to labetalol, hydrochlorothiazide, or sulfonamide-derived drugs, anuria. Relative: diabetes mellitus, hyperthyroidism, pheochromocytoma (labetalol may paradoxically elevate blood pressure), severe renal impairment (Cr Cl <30 m L/min for thiazide efficacy).
Hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs.,Active liver disease or previous methyldopa-induced liver disorders.,Anuria or severe renal impairment (creatinine clearance <30 m L/min).
Avoid tyramine-rich foods (aged cheese, cured meats, fermented soy products) due to potential hypertensive crises. Limit caffeine intake; may increase heart rate. Avoid excessive potassium-rich foods or supplements unless monitored due to hydrochlorothiazide's potassium-wasting effect. Take with food to reduce GI upset.
Avoid excessive potassium-rich foods (bananas, oranges, spinach) unless directed, as thiazide can cause potassium loss; however, monitor for hypokalemia. Limit sodium intake to enhance antihypertensive effect. Methyldopa absorption is not significantly affected by food.
First trimester: No clear association with major malformations in limited human data; labetalol crosses placenta. Second/third trimester: Potential fetal bradycardia, hypotension, hypoglycemia, and respiratory depression; intrauterine growth restriction reported with chronic use.
First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Second and third trimesters: Risk of intrauterine growth restriction (IUGR), oligohydramnios, and renal dysplasia. Neonatal: Folate deficiency, megaloblastic anemia, and potential for methotrexate-like toxicity if used near term.
Labetalol is excreted into breast milk in low amounts (M/P ratio ~0.6-0.8); generally considered compatible with breastfeeding; monitor infant for bradycardia and hypotension.
Pyrimethamine (component of ALDOCLOR-150) is excreted into breast milk in small amounts; the M/P ratio is not well established. Sulfadoxine (component) is also excreted. Theoretical risk of kernicterus in jaundiced infants due to sulfonamide displacement of bilirubin. Use with caution, especially in preterm or G6PD-deficient infants. The benefits of breastfeeding should outweigh potential risks; alternative antimalarials are preferred.
No standard dose adjustment required; however, pregnancy may alter labetalol pharmacokinetics (increased clearance, decreased half-life) potentially necessitating dose titration based on clinical response.
No standard dose adjustment required, but consider increased folic acid supplementation (5 mg daily) to reduce teratogenic risk. Due to increased glomerular filtration rate (GFR) in pregnancy, renal clearance may be enhanced; however, ALDOCLOR-150 is typically used as a single dose and pharmacokinetic data do not support routine dose adjustment. Individualize based on clinical response and toxicity monitoring.
Trandate HCT combines labetalol (alpha/beta blocker) and hydrochlorothiazide. Monitor heart rate, blood pressure, and electrolytes. Avoid in asthma, COPD, bradycardia, heart block, and anuria. Taper if discontinuing. May mask hypoglycemia in diabetics. Can cause orthostatic hypotension; dose at bedtime initially.
ALDOCLOR-150 combines chlorothiazide (a thiazide diuretic) and methyldopa (a central alpha-2 agonist). Monitor for hypokalemia and hyponatremia due to thiazide; methyldopa may cause positive Coombs test (hemolytic anemia risk) and hepatotoxicity. Titrate methyldopa slowly to avoid sedation. Use with caution in renal impairment (Cr Cl <30 m L/min reduces thiazide efficacy).
Take exactly as prescribed, usually once daily, with or without food.,Do not stop suddenly; tapering is necessary to avoid rebound hypertension.,May cause dizziness or lightheadedness; rise slowly from sitting or lying.,Avoid alcohol; it can worsen dizziness and side effects.,Inform your doctor if you experience slow heartbeat, fainting, swelling of feet/ankles, or unusual weight gain.,May cause photosensitivity; use sunscreen and protective clothing.,Monitor blood pressure regularly at home.
Take medication exactly as prescribed, usually once or twice daily.,May cause dizziness or drowsiness; avoid driving until effects are known.,Stand up slowly to prevent falls from low blood pressure.,Report unexplained fever, fatigue, or jaundice (signs of liver issues).,Avoid alcohol, which enhances sedative effects.,Do not stop abruptly (risk of rebound hypertension).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRANDATE HCT vs ALDOCLOR-150, answered by our medical review team.
TRANDATE HCT is a Antihypertensive Combination that works by TRANDATE HCT is a combination of labetalol, a non-selective beta-blocker with selective alpha-1 blocking activity, and hydrochlorothiazide, a thiazide diuretic. Labetalol reduces peripheral vascular resistance via alpha-1 blockade and decreases heart rate and cardiac output via beta-blockade. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, promoting diuresis and reducing plasma volume.. ALDOCLOR-150 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRANDATE HCT and ALDOCLOR-150 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRANDATE HCT is: Oral: 100 mg labetalol/25 mg hydrochlorothiazide twice daily, titrated based on blood pressure response; maximum 1200 mg labetalol/300 mg hydrochlorothiazide daily.. The standard adult dose of ALDOCLOR-150 is: ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRANDATE HCT and ALDOCLOR-150 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRANDATE HCT is classified as Category C. First trimester: No clear association with major malformations in limited human data; labetalol crosses placenta. Second/third trimester: Potential fetal bradycardia, hypotension, . ALDOCLOR-150 is classified as Category C. First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.